357.27
前日終値:
$345.37
開ける:
$347.59
24時間の取引高:
1.18M
Relative Volume:
0.94
時価総額:
$17.06B
収益:
$4.03B
当期純損益:
$-182.84M
株価収益率:
-95.01
EPS:
-3.7603
ネットキャッシュフロー:
$391.29M
1週間 パフォーマンス:
+13.26%
1か月 パフォーマンス:
+22.00%
6か月 パフォーマンス:
+108.65%
1年 パフォーマンス:
+82.95%
Charles River Laboratories International Inc Stock (CRL) Company Profile
名前
Charles River Laboratories International Inc
セクター
電話
781-222-6000
住所
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, A, IQV
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International Inc
|
357.27 | 17.06B | 4.03B | -182.84M | 391.29M | -3.7603 |
|
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
|
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-30 | 再開されました | UBS | Buy |
| 2026-08-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2026-07-20 | ダウングレード | CLSA | Outperform → Hold |
| 2026-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | アップグレード | CLSA | Hold → Outperform |
| 2026-04-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-11-17 | アップグレード | Argus | Hold → Buy |
| 2025-11-06 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-09-09 | アップグレード | Jefferies | Hold → Buy |
| 2025-07-09 | アップグレード | Citigroup | Neutral → Buy |
| 2025-05-23 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | アップグレード | TD Cowen | Hold → Buy |
| 2025-05-08 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-03-21 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-04 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-03 | アップグレード | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | ダウングレード | UBS | Buy → Neutral |
| 2024-11-18 | ダウングレード | CLSA | Hold → Underperform |
| 2024-11-07 | アップグレード | CLSA | Underperform → Hold |
| 2024-10-23 | 開始されました | CLSA | Underperform |
| 2024-10-14 | 開始されました | Redburn Atlantic | Sell |
| 2024-10-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-01 | ダウングレード | Citigroup | Neutral → Sell |
| 2024-08-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | ダウングレード | Argus | Buy → Hold |
| 2024-06-07 | 開始されました | Mizuho | Neutral |
| 2024-06-06 | 開始されました | Goldman | Buy |
| 2024-02-15 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-09-13 | 開始されました | TD Cowen | Market Perform |
| 2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-02-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-12 | ダウングレード | Jefferies | Buy → Hold |
| 2022-09-30 | アップグレード | Jefferies | Hold → Buy |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-08-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 開始されました | Guggenheim | Neutral |
| 2022-04-25 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-07 | 開始されました | Stephens | Overweight |
| 2022-02-17 | 繰り返されました | BofA Securities | Buy |
| 2022-02-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-02-17 | 繰り返されました | Deutsche Bank | Buy |
| 2022-02-17 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-17 | 繰り返されました | UBS | Buy |
| 2021-08-05 | 再開されました | Credit Suisse | Neutral |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-09-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-07-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-05-13 | アップグレード | UBS | Neutral → Buy |
| 2020-04-21 | ダウングレード | Jefferies | Buy → Hold |
| 2020-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 開始されました | Deutsche Bank | Buy |
| 2020-02-18 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | アップグレード | Goldman | Neutral → Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-10-18 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 開始されました | SVB Leerink | Outperform |
| 2019-04-30 | 再開されました | Evercore ISI | Outperform |
| 2018-12-14 | 開始されました | Deutsche Bank | Buy |
| 2018-10-09 | 開始されました | UBS | Neutral |
| 2018-08-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Charles River Laboratories International Inc (CRL) 最新ニュース
Charles River Laboratories’ Q3 2026 Earnings: What to Expect - Yahoo Finance
Charles River Laboratories International (CRL) Has Fresh Attention, But What Is Behind It? - Simply Wall Street
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories International, Inc. Estimates – NYSE:CRL - TradingView
Charles River Laboratories (CRL) Partners with FDA and Labcorp t - GuruFocus
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Finviz
Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5 - Yahoo Finance
$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today - Benzinga
Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype - Timothy Sykes
Charles River Laboratories International Jumps 7.3% in Broad Rally - AlphaStreet
Charles River Labs Stock Jumps As Street Hikes Targets - StocksToTrade
Charles River Laboratories stock hits 52-week high at 333.31 USD - Investing.com
Charles River Laboratories stock hits 52-week high at 333.31 USD By Investing.com - Investing.com South Africa
Is Charles River Laboratories International Inc (CRL) Overvalued After 5.1% Rally? GF Value Says Overvalued - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Dilution adjustment of Charles River Laboratories International, Inc. – XETR:RV6 - TradingView
Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00 - ad-hoc-news.de
AI-Driven Drug Discovery Boosts Charles River Laboratories (CRL) Prospects - GuruFocus
Citrini Bets on Life Sciences Stocks After Claude AI Drug Study - Bloomberg.com
Charles River Laboratories International (CRL) Earnings Beat Puts Fair Value Back In Focus - Simply Wall Street
Charles River Laboratories International, Inc. (CRL) Options ChainYahoo Finance - Yahoo! Finance Canada
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
ETFs Are Net Sellers of Charles River (CRL) on Wednesday - Yahoo Finance
Apollo Orchestrate digitizes lab workflows - Select Science
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
CRLFuture Testing Mix Shift And Create The Future Program Will Support Stable Outlook - Simply Wall Street
Is Stem Cell Testing Deal Altering The Investment Case For Charles River Stock? - Simply Wall Street
JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310 - Yahoo Finance
Charles River partners with Magellan Stem Cells on cell therapy - Yahoo Finance
Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy - Yahoo Finance
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $324.87, Implies 8% Upside - TradingView
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera - GlobeNewswire Inc.
Form 144 CHARLES RIVER LABORATORIES INTERNATIONAL For: 12 October By Investing.com - Investing.com Canada
Is Charles River Laboratories International (CRL) Fairly Valued After The Apollo Orchestrate Launch? - Simply Wall Street
Q2 2026 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - Business Wire
Charles River and Autolomous launch Apollo Orchestrate for digital laboratory execution - BioSpectrum Asia
Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com Nigeria
Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com
Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com India
Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com UK
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
PGNY or CRL: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Yahoo! Finance Canada
Charles River Gains 75.8% in a Year: What's Driving the Rally? - TradingView
Could Apollo Orchestrate Launch Shift Charles River Labs Stock Narrative - Simply Wall Street
Charles River Laboratories International Inc (CRL) 財務データ
収益
当期純利益
現金流量
EPS
Charles River Laboratories International Inc (CRL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FOSTER JAMES C | Director |
Oct 22 '26 |
Proposed Sale |
350.00 |
24,042 |
8,414,700 |
0 |
| FOSTER JAMES C | Director |
Oct 22 '26 |
Sale |
350.00 |
24,042 |
8,414,700 |
31,596 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Oct 21 '26 |
Sale |
344.41 |
2,156 |
742,548 |
4,807 |
| Parisotto Shannon M | Officer |
Oct 21 '26 |
Proposed Sale |
344.41 |
2,156 |
742,548 |
0 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Oct 21 '26 |
Option Exercise |
244.41 |
2,156 |
526,948 |
6,963 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Oct 05 '26 |
Option Exercise |
208.44 |
981 |
204,480 |
5,788 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Oct 05 '26 |
Sale |
308.44 |
981 |
302,580 |
4,807 |
| Parisotto Shannon M | Officer |
Oct 05 '26 |
Proposed Sale |
314.56 |
981 |
308,580 |
0 |
| Coleman Glenn | EVP & Chief Financial Officer |
Sep 30 '26 |
Buy |
297.43 |
10 |
2,974 |
27,762 |
| FOSTER JAMES C | Director |
Aug 25 '26 |
Option Exercise |
199.42 |
33,561 |
6,692,845 |
65,157 |
大文字化:
|
ボリューム (24 時間):